Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioInvent has entered into a strategic collaboration with Genentech to co-develop and commercialize the antibody BI-204, but will retain the rights to the product outside North America as part of the deal.
Subscribe to our email newsletter
BioInvent believes the deal could accelerate its product development as retaining the North American rights gives the company an opportunity to increase participation and involvement in the antibody. BI-204 will be developed as a treatment against multiple cardiovascular conditions.
Genentech will make an upfront payment of $15 million to BioInvent and, in addition, BioInvent could receive further milestone payments of up to $175 million as well as royalties on sales in North America.
Under the terms of the agreement, Genentech and BioInvent will be jointly responsible for clinical development. Genentech will be responsible for any commercialization of the drug in North America.
BI-204, which is in preclinical development, addresses the prevention of a cardiovascular event such as a myocardial infarction or stroke in patients at risk. Preclinical studies suggest that this treatment could reduce atherosclerotic plaque burden, and thereby decrease the risk of a secondary cardiovascular event.